ASCO GU 2024

Cabo + IO: Interesting but not practice changing?!

BRCAAway - practice changing or hypothesis generating…

Combination vs. monotherapy - a great new option for…

Gleason 3+3 - cancer or not?

Cognitive function in ART treatment

Higher radiation is effective in high-risk PCA

Olaparib + Arbiraterone better compared to either alone

Therapy Intensification Still Neglected in mHSPC

Further testing before olaparib combination

Stockholm3 validated in multiethnic cohort

Combination of cabozantinib & checkpoint inhibitor

Enzalutamide therapy as option for biochemical…

Evaluating the recombination-repair mutations in…

Localized PCa - news for radiotherapy and biochemical…

Insights and news for mCRPC

Still a difficult time for androgenic inhibitors in…

Quality of life under intensive therapy

First positive study of IO therapy in mCRPC

BRCAaway - PARP combination study

Combination NHT + PARP makes sense

What about the clinical benefit?

Salvage radiation with anti-androgen superior to…

Long-term dose escalation - Therapy in high-risk…

Dose de-escalation in different ways

Une période encore difficile pour les inhibiteurs…

Gleason 3+3 ska vi kalla de cancer eller inte?

Kombination av cabozantinib och immunterapi

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO…

Kognitiv påverkan av abirateron och enzalutamid?

SEPTA calismasi: Stockholm3 un multietnik hasta…

BRCAAway - PARP hämmare, abiraterone eller i…

Post-RP salvage radyoterapi hormonoterapi ile konbine…

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi) Orta…

The emerging field of biomarkers in bladder cancer

ADC + ICI: new data for platinum-refractory bladder…

New standard of care, but still open questions!

Perioperative adjuvant therapy in urothelial cancer

Update on EV-302

EV as standard in 3rd line mUC

Should we start forgetting the Galsky Criteria in…

Adjuvant therapy in urothelial carcinoma : is the…

Adjuvant Nivolumab Shows Promise in Boosting Long-Term…

Biomarker update

EV + Pembro new first-line standard in localized…

ASCO GU24 - Highlights in Bladder cancer

Pembrolizumab adjuvant in bladder cancer

Highlights in bladder cancer at ASCO GU24

Another success for an ICI?

Update M1 urothelial cancer

HER2 and bladder cancer

Tratamiento adyuvante en cancer urotelial: ¿está…

Encore un succès pour une ICI ?

Novedades sobre EV-302

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

¿Deberíamos empezar a olvidarnos de los Criterios de…

No surprise with the QoL data

Adjuvant therapy in kidney cancer: Is immunotherapy the…

Subcutaneous vs. intravenous application: ready for…

Better QoL with Belzutifan

Long-term follow-up of first-line trials

Tumorburden and outcome

Durable effects of Ipi-Nivo

Long-Term Data on NIVO+IPI in aRCC

Perioperative treatment in renal cell carcinoma - did…

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark…

Highlights in kidney cancer at ASCO GU24

Subcutaneous Nivolumab Matches IV Formulation in Clear…

Practice changing adjuvant therapy?!

Overall survival benefit - Pembro after surgery

Belzutifan: Updates on QoL

Cabozantinib Plus Atezolizumab in Adrenocortical…

ASCO GU24 - Highlights in renal cell carcinoma

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24